Skip to main content
4723 search results for:

Mantle Cell Lymphoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 01-12-2024 | Mantle Cell Lymphoma | OriginalPaper

    Colonic lymphomatous polyposis mantle cell lymphoma: a case report and review of literature

    Non-Hodgkin lymphoma (NHL) of the digestive tract is the most common extraganglionic lymphoma. Approximately 15–30% of primary extraganglionic lymphomas occur in the gastrointestinal tract, accounting for 1–10% of all gastrointestinal cancers [ 1 – …3

  2. 11-05-2024 | Mantle Cell Lymphoma | Online First

    Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma

    Cyclin D1 protein-positive diffuse large B cell lymphoma (DLBCL) has an immunophenotype of CD5(−) cyclin D1(+) SOX11(−), and most cases lack a CCND1 rearrangement and have a gene expression profile of DLBCL. Rarely, cyclin D1 protein-positive …

  3. 03-02-2024 | Mantle Cell Lymphoma | OriginalPaper

    Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study

    To explore the optimal treatment for young patients with untreated mantle cell lymphoma (MCL), we compared the efficacy and safety of R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone/rituximab, dexamethasone …

  4. 03-04-2024 | Disseminated Intravascular Coagulation | Online First

    Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma

  5. 17-04-2024 | Mantle Cell Lymphoma | Online First

    Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey

    Mantle cell lymphoma (MCL) pathogenesis is strongly related to the role of the tumor immune microenvironment (TIME) in which MCL cells proliferate. TIME cells can produce growth signals influencing MCL cells’ survival and exert an antitumoral …

  6. Open Access 01-12-2024 | Mantle Cell Lymphoma | Letter

    Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

    Mantle cell lymphoma (MCL) is a subtype of B-cell lymphomas characterized by deregulation of cell cycle progression at the G 1 -S phase transition as a consequence of cyclin D1 overexpression [ 1 , 2 ]. Palbociclib, a highly selective …

  7. Open Access 18-03-2024 | Mantle Cell Lymphoma | OriginalPaper

    Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor

    Mantle cell lymphoma (MCL) is a rare hematologic B cell malignancy that represents less than 10% of all cases of non-Hodgkin lymphoma (NHL) [ 1 ]. Response rates to initial therapy are generally high [ 2 ]; however, almost all patients eventually …

  8. 27-01-2024 | Mantle Cell Lymphoma | ReviewPaper

    Pirtobrutinib in relapsed or refractory mantle cell lymphoma: a profile of its use

    Pirtobrutinib (Jaypirca®), an oral, small molecule, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, is a promising new treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL), including those who have …

  9. Open Access 01-03-2024 | Mantle Cell Lymphoma | OriginalPaper

    The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma

    Mantle cell lymphoma (MCL) was identified as a specific type of lymphoma in 1992 (Banks et al. 1992 ). It is a rare subtype of aggressive B cell non-Hodgkin lymphoma (NHL), accounting for 3% to 10% of adult NHL, the incidence is on the rise, with a …

  10. Open Access 01-12-2024 | Mantle Cell Lymphoma | OriginalPaper

    The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

    Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy with dismal outcomes. To dissect the …

  11. Open Access 09-03-2024 | Mantle Cell Lymphoma | Online First

    Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group

    Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients. We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to explore the …

  12. 25-02-2024 | Mantle Cell Lymphoma | Online First

    Should We Test for MYC-Rearrangement in Mantle Cell Lymphoma?—An Illustrative Report

  13. Open Access 01-12-2023 | Mantle Cell Lymphoma | OriginalPaper

    Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

    Mantle cell lymphoma (MCL), accounting for 3–10% of non-Hodgkin lymphoma, is a mature B cell lymphoma characterized by cyclin D1 rearrangement. MCL occurs mostly in the lymph nodes with frequent extranodal involvement, and most patients have …

  14. Open Access 09-01-2024 | Ibrutinib | OriginalPaper

    Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance

    Efficacy and safety data for ibrutinib in Japanese patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) were limited at the time of its approval in Japan. All-case post-marketing surveillance was conducted in Japanese R/R MCL …

  15. Open Access 29-12-2023 | Ibrutinib | OriginalPaper

    Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma

    Mantle cell lymphoma (MCL) represents approximately 3% of all malignant lymphoma cases in Japan and occurs more commonly in elderly men [ 1 , 2 ]. Unfortunately, there is no cure for MCL, and nearly all patients inevitably relapse [ 3 , 4 ].

  16. 02-01-2024 | Mantle Cell Lymphoma | Online First

    Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China

    Blastoid or pleomorphic mantle cell lymphoma (B/P-MCL) is characterized by high invasiveness and unfavorable outcomes, which is still a challenge for treating MCL. This retrospective study was performed to comprehensively analyze the clinical …

  17. 01-12-2023 | Mantle Cell Lymphoma | Online First

    Indolent mantle cell lymphoma of renal significance

    A 62-year-old Caucasian male was admitted to our hospital in April 2019 for the investigation of stage 3 acute kidney injury (AKI). He had been diagnosed with mantle cell lymphoma (MCL) two years earlier from a lymph node biopsy demonstrating CD20 …

  18. Open Access 01-12-2023 | Mantle Cell Lymphoma | ReviewPaper

    CAR T-Cell therapy for the management of mantle cell lymphoma

    The authors provide a synopsis of chimeric antigen receptor T-cell therapy for mantle cell lymphoma, including an overview of the efficacy data from the trials of agents such as brexucabtagene autoleucel and guidance on managing the associated toxicities.

  19. 26-10-2023 | Mantle Cell Lymphoma | Letter

    Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement

  20. Open Access 08-08-2023 | Mantle Cell Lymphoma | OriginalPaper

    The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis

    Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma and commonly used induction immunochemotherapies include the anti-CD20 antibody rituximab. However, efficacy data for rituximab regarding overall survival (OS) in first line MCL …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.